You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel Insulators in Silicon-on-Insulator Substrates to Improve Nuclear Physics Sensors and Circuits
SBC: CAPORUS TECHNOLOGIES INC Topic: C5333cC53-33c-271423Active pixel sensors have been developed and implemented in a wide array of applications, including image sensors for cameras, sensors for medical imaging, and as detectors for nuclear physics investigations with the Relativistic Heavy Ion Collider and the Large Hadron Collider. Many of these applications, including nuclear physics detectors, medical imaging sensors, and sensors for ...
SBIR Phase II 2023 Department of Energy -
SBIR Phase I:Creation of antimicrobial MyoMatrix for functional muscle regeneration in a porcine model of volumetric muscle loss
SBC: GENASSIST INC Topic: BMThe broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop an antimicrobial muscle-regenerating biomaterial into a commercial-ready product and address volumetric muscle loss injuries. In the context of defense medicine, severe muscle trauma often occurs in environments where external factors such as sterility are not well-controlled. Th ...
SBIR Phase I 2023 National Science Foundation -
SBIR Phase I:Directed evolution of site-specific bacterial transposase genes to alter specificity and efficiency of insertion of large DNA segments into restorable gene fusions
SBC: SYNTHETIC VECTOR DESIGNS, LLC Topic: BTThe broader impact of this Small Business Innovation Research (SBIR) Phase I project will be to develop methods to facilitate the efficient, reproducible insertion of large DNA segments into stable locations on bacterial vectors, viral and non-viral shuttle vectors, and the chromosomes of prokaryotic and eukaryotic host cells comprising novel target sequences plus helper and donor vectors that cou ...
SBIR Phase I 2023 National Science Foundation -
SBIR Phase II: Building Mathematical Thinking and Problem-solving Skills Together Through Play
SBC: MATHBRIX LLC Topic: LCThis SBIR Phase I project will develop a machine learning-assisted family math preparation program that will help and encourage parents to provide early math instruction to young children, ages 4-8. Along with reading, developing mathematical proficiency is arguably one of the most important skills for young children to acquire, particularly with the growing importance of STEM (science, technology ...
SBIR Phase II 2023 National Science Foundation -
Computer Vision Under Strict Security Constraints: Applications for Robotics
SBC: MONA MARIE CORPORATION Topic: X224OCSO1Proposed is robotic lawn mower developed and commercialized by the proposing company – Hire Henry. The focus of this Phase I proposal is to quantify the potential impact for fully autonomous, fully electric robotic lawn mowing on United States Air Force Bases. This proposal lays the ground work for future work, which focuses on developing computer vision models for robotic mowing specifically f ...
SBIR Phase I 2023 Department of DefenseAir Force -
Increasing Biomass Of TKS/Kazhak Rubber Dandelion To Increase Yields And Reduce Cost Of TKS Rubber
SBC: KULTEVAT, Inc Topic: 82Kultevat Inc. aims to produce natural rubber from Taraxacum kok-saghyz (TKS) at scale toachieve high quality product at a price point that is attractive to customers in particular to US basedcompanies. To date the economics of growing TKS and extracting rubber from its roots at a pricepoint that is competitive with Hevea rubber has not been demonstrated. During Phase I research anRNAi gene silenci ...
SBIR Phase II 2023 Department of Agriculture -
Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy
SBC: NEWVENTUREIQ LLC Topic: 102Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring
SBC: Axioforce LLC Topic: NIBIBPROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing a clinical diagnostic tool for age-related cochlear synaptopathy.
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIAAge-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. Whil ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma
SBC: Sarya, LLC Topic: 102PROJECT SUMMARY Sarya LLC (Sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this Fast-Track STTR is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2nd most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate de ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health